Bharat Parenterals Ltd Q3 FY26 Earnings Analysis

- Standalone business is expected to achieve 12%-14% revenue growth in FY '26, with a 15%-17% EBITDA margin. - FY '27 standalone growth guided at 10%-12% annually over the next five years. - Innoxel Lifesciences targets Rs. 110-135 crores revenue in FY '27, with EBITDA between Rs. 35-50 crores and poised to turn PAT positive. - Commercial CMO supplies to start from Q1 FY '27, adding revenue streams beyond milestone receipts (Rs. 65-70 crores expected in FY '26). - Varenyam Healthcare aims to cross Rs. 100 crore revenue in 18-24 months, with potential to reach Rs. 250-300 crores subsequently. - Institutional orders and product pipeline expected to drive revenue ramp-up in H2 FY '26 and beyond. - Management plans to maintain stable margins and optimize operational efficiency amid planned capacity upgrades.

- Standalone business expected to deliver 12% to 14% revenue growth in FY '26 with EBITDA margins of 15% to 17%. - Operational stability anticipated with better H2 FY '26 performance compared to H1. - Innoxel Lifesciences projected to break even operationally in FY '26, with revenues of Rs. 110 to Rs. 135 crores and EBITDA between Rs. 35 to Rs. 50 crores for FY '27. - Varenyam Healthcare aims for Rs. 60 to Rs. 65 crores revenue in FY '26, achieving 20%-21% growth and 10% PAT. - Consolidated profitability expected to improve with positive PAT likely by FY '27, supported by core standalone recovery and Innoxel’s progress. - Long-term standalone business growth projected at 10% to 12% over five years. - Overall, sustainable growth and improved margins are anticipated in FY '27 and beyond.

- Varenyam Bio total CapEx outlay is around Rs. 120 crores for the entire plant. - Rs. 35 to 40 crores of investment has already been completed through internal accruals. - Construction of general block is complete; oncology block construction has begun. - Plant expected to be fully operational by FY '26 end. - Regulatory approval phase to start early FY '27. - Innoxel currently managing OPEX through milestone and licensing revenues; promoters step in for shortfalls. - No concrete plans for external strategic investment in Innoxel currently, but all possibilities are being considered. - Any future strategic investment discussions will be communicated when concrete.

- Innoxel is currently managing its operations through internal accruals generated from milestone and licensing revenues. - Wherever there is a shortfall, promoters are stepping in to cover the gaps. - No specific plans for new fundraising have been announced as of now. - The company is open to all possibilities, including internal accruals, promoter receivables, or external investors. - Any strategic investment, if arises, will be communicated when concrete. - Presently, there is no immediate need for additional capital infusion.

- Bharat Parenterals has a significant institutional order of Rs. 210 crores received last year. - The first tranche of this institutional order was completed in Q1 FY '26. - The second and third tranches are expected to be completed in the second half (H2) of FY '26. - The last tranche of this order is expected to be completed in Q1 of the next financial year. - Order execution is on track and contributes to the anticipated 12-15% year-on-year revenue growth for the standalone business. - Additionally, there is an expected growth and seasonality with some export dispatches deferred to Q3. - Overall, execution of current order book is expected to strengthen momentum in H2 FY '26.